Evaluating the Efficacy of Thrombectomy in Distal Vessel Occlusions: J Mocco, MD, MS
February 11th 2025The director of the Cerebrovascular Center at Mount Sinai talked about findings from recent trials presented at ISC 2025 investigating thrombectomy for distal vessel occlusions. [WATCH TIME: 4 minutes]
Evolution of Stroke Treatment on Display at ISC 2025: Andrei Alexandrov, MD
February 10th 2025The professor and chair of the neurology department at the University of Arizonia, Phoenix, gave clinical insights on the notable progress in the stroke treatment world, highlighted by advances presented at the 2025 International Stroke Conference. [WATCH TIME: 3 minutes]
Expanding the Time Window for Intravenous Thrombolysis in Ischemic Stroke: Min Lou MD, PhD
February 10th 2025The professor at the Second Affiliated Hospital of Zhejiang University’s School of Medicine discussed findings from a trial suggesting that intravenous thrombolysis could benefit patients with ischemic stroke up to 24 hours after symptom onset. [WATCH TIME: 8 minutes]
Using Practical Training to Enhance Movement Disorder Care: Clarisse Goas MSN, APRN-CNP
February 7th 2025The movement disorders nurse practitioner at The Ohio State University Wexner Medical Center talked about a meeting that equips nurse practitioners and physician assistants to improve movement disorder patient care. [WATCH TIME: 5 minutes]
Mechanism and Promise Behind SPN-830 for Parkinson Disease: Stuart Isaacson, MD, FAAN
February 7th 2025The director of the Parkinson’s Disease and Movement Disorders Center of Boca Roaton, Florida, gave clinical insight on the function of a newly approved therapy for Parkinson disease, a common neurodegenerative disorder. [WATCH TIME: 3 minutes]
Patient Perspective on the Role of Social Support in Managing Narcolepsy: Julie Flygare, JD
February 5th 2025The president and CEO at Project Sleep talked about the foundational role of social connections and peer support in improving quality of life for individuals with narcolepsy. [WATCH TIME: 5 minutes]
Reaction and Significance of SPN-830 Approval for Parkinson Disease: Stuart Isaacson, MD, FAAN
February 5th 2025The director of the Parkinson’s Disease and Movement Disorders Center of Boca Raton, Florida, discussed SPN-830, the first and only FDA-approved subcutaneous apomorphine infusion device for patients with Parkinson disease. [WATCH TIME: 2 minutes]
Medical Insights on the Recent Approval of AXS-07 for Acute Migraine Treatment: Stewart Tepper, MD
February 5th 2025The professor of neurology at the Geisel School of Medicine at Dartmouth shared his reaction to the recent FDA approval of AXS-07, a combination of meloxicam and rizatriptan, as a new therapy for acute migraine management. [WATCH TIME: 4 minutes]
Clinical Perspective on Newly Approved Combination Therapy for Migraine: Richard B. Lipton, MD
February 4th 2025The director of the Montefiore Headache Center at Albert Einstein College of Medicine discussed the recent FDA approval of a new migraine treatment that combines rizatriptan and meloxicam. [WATCH TIME: 5 minutes]
What to Expect at MDA’s 2025 Clinical and Scientific Conference: Barry J. Byrne, MD, PhD
January 30th 2025The chief medical advisor at the Muscular Dystrophy Association shared key highlights of what attendees can expect at the 2025 MDA Clinical and Scientific Conference. [WATCH TIME: 4 minutes]
Enhancing Multiple Sclerosis Diagnosis and Early Treatment Strategies: David A. Hafler, MD, FANA
January 29th 2025The William S. and Lois Stiles Edgerly Professor of Neurology at Yale School of Medicine talked about refining multiple sclerosis in line with the updated diagnostic criteria. [WATCH TIME: 5 minutes]
Feasibility and Scalability of Amprion’s Assay for Synucleinopathy Diagnosis: Russ Lebovitz, MD, PhD
January 24th 2025The chief executive officer and cofounder of Amprion discussed the integration process of a novel a-synuclein seed amplification assay used to distinguish seeds from Lewy bodies and glilal cytoplasmic inclusions. [WATCH TIME: 2 minutes]